Heart Disease Company Tenaya Therapeutics Files For $100M US IPO

Tenaya Therapeutics TNYA is quickstepping into a $100 million NASDAQ debut under the TNYA symbol. The company filed an SEC prospectus on Friday.
The biotech firm is attacking heart disease through three different angles - gene therapy, cellular regeneration, and precision medicine.
Its $106 million series C, pulled off back in March, was designed to help propel several preclinical programs toward the clinic, including gene therapy for hypertrophic cardiomyopathy (HCM) and set up a site in the Bay Area to manufacture vectors.
Tenaya is starting with an AAV-based gene therapy targeting mutations in the MYBPC3 gene, the leading genetic cause of HCM.
According to its SEC-1 filing, it plans INDs for its gene therapy and precision medicine platforms in 2022.
In addition to VC backers The Column Group and Casdin Capital, Tenaya's key shareholders include Walmart heir Thomas Walton.